Evommune is a Biotech company based in Palo Alto. It has raised $115M in total funding. Latest round: Series C.
Evommune funding overview
Evommune is a Biotech company based in Palo Alto. Evommune has raised $115M in total disclosed funding. That places its disclosed total in the $100M–$250M range. Its most recent disclosed round is a Series C announced in October 2024. The round record for Evommune runs through 2024; nothing later has been disclosed. Investors on record include RA Capital Management, Sectoral Asset Management, B Capital, Marshall Wace, Avego Bioscience Capital, Longwood Fund and 12 others. 18 distinct backers are named across the disclosed rounds.
Evommune at a glance
Total raised
$115M
Latest round
Series C
Latest round date
October 2024
Industry
Biotech
Headquarters
Palo Alto
Notable investors
RA Capital Management, Sectoral Asset Management, B Capital, Marshall Wace, Avego Bioscience Capital, Longwood Fund, RTW Investments, ADAR1 Capital Management
Frequently asked about Evommune funding
How much has Evommune raised?
Evommune has raised $115M in total disclosed funding across the rounds on record.
Who has invested in Evommune?
RA Capital Management, Sectoral Asset Management, B Capital, Marshall Wace, Avego Bioscience Capital, Longwood Fund are named among the investors backing Evommune.
What was the latest Evommune funding round?
The most recent disclosed round is a Series C, announced in October 2024.
Where is Evommune based?
Evommune is based in Palo Alto.
What sector does Evommune operate in?
Evommune is tracked under Biotech from Palo Alto, with $115M in disclosed funding.
When did Evommune last raise?
The last disclosed Evommune round closed in October 2024 at Series C.
Every Evommune figure above comes from filings and announced rounds in the StartupFundraising company database and is revised as new rounds are recorded. The lists below compare Biotech companies in Palo Alto at a similar stage.
